Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: Rationale, current evidence and future directions  by Weeder, Pepijn D. et al.
ReviewMachine perfusion in liver transplantation as a tool to prevent
non-anastomotic biliary strictures: Rationale, current evidence
and future directions
Pepijn D. Weeder, Rianne van Rijn, Robert J. Porte⇑
Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center
Groningen, Groningen, The NetherlandsSummary
The high incidence of non-anastomotic biliary strictures (NAS)
after transplantation of livers from extended criteria donors is
currently a major barrier to widespread use of these organs.
This review provides an update on the most recent advances in
the understanding of the etiology of NAS. These new insights give
reason to believe that machine perfusion can reduce the inci-
dence of NAS after transplantation by providing more protective
effects on the biliary tree during preservation of the donor liver.
An overview is presented regarding the different endpoints that
have been used for assessment of biliary injury and function
before and after transplantation, emphasizing on methods used
during machine perfusion. The wide spectrum of different
approaches to machine perfusion is discussed, including the
many different combinations of techniques, temperatures and
perfusates at varying time points. In addition, the current under-
standing of the effect of machine perfusion in relation to biliary
injury is reviewed. Finally, we explore directions for future
research such as the application of (pharmacological) strategies
during machine perfusion to further improve preservation. We
stress the great potential of machine perfusion to possiblyJournal of Hepatology 20
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Orthotopic liver transplantation is currently the only available
life-saving treatment for patients with end-stage liver disease.
Unfortunately, the number of organs needed for transplantation
greatly surpass the supply, prompting strict selection criteria
for transplant candidates and long waiting lists for those patients
that reach candidate status. As a result of this shortage about 15%
of patients die while on the waiting list [1]. Additionally, accord-
ing to studies of death certiﬁcates, about 60,000 patients die of
liver disease annually in the United States [2]; many of whom
could (theoretically) have been treated with a liver transplant.
When only waitlist mortality is considered, the magnitude of
the problem of end-stage liver disease is grossly underestimated.
In fact, only about 1.5% of liver disease related mortality concerns
waitlisted patients [3].
The grave shortage of livers available for transplantation
causes the transplant community to continuously push the
boundaries to increase the availability of organs. As a part of this
effort, criteria for donor liver selection have been progressively
expanded, allowing the usage of more suboptimal or compro-
mised grafts. Livers from donors that fall outside of standard cri-
teria, also known as ‘extended criteria donors (ECDs), are
increasingly considered for transplantation during the past dec-
ades [4]. For example, in the United Kingdom 42% of transplanted
livers now come from donation after circulatory death (DCD)
donors, as opposed to donation after brain death (DBD) [5]. The
most important other criteria that are being widened include
donor age, blood type ABO incompatibility, steatosis, and infec-
tious diseases in the donor [6,7]. The increased acceptance of liv-
ers from ECDs in the past two decades has contributed
signiﬁcantly to the expansion of the donor organ pool [8,9].
Today, the survival rate of patients that receive a DCD liver
graft is approximately similar to DBD recipients [10–13].
However, the transplantation of DCD liver grafts is associated15 vol. 63 j 265–275
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Fig. 1. Radiological and histological examples of bile duct injury in a donor liver. (A) Cholangiogram revealing mild non-anastomotic strictures in a donor liver. (B)
Cholangiogram showing severe non-anastomotic strictures in a donor liver. (C) Histology of a donor bile duct (hematoxylin & eosin staining) with approximately 50%
detachment and loss of the luminal epithelium (lumen indicted by #), but well preserved bile duct wall stroma (asterix) and peribiliary glands (dotted lines). (D) Histology
of a donor bile duct (hematoxylin & eosin staining) with a well preserved arteriole (arrow) as part of the PVP. (E and F) Histology of a donor bile duct (hematoxylin & eosin
staining) with necrosis of bile duct wall stroma (asterix), arteriolonecrosis, and loss of epithelial cells in the peribiliary glands (dotted lines). The arrow indicates a
peribiliary gland with a complete loss of epithelial cells.
Reviewwith around 10% lower 1-year graft survival rate, compared to
DBD livers and a markedly higher incidence of biliary complica-
tions [14–17]. The incidence of NAS varies between 4% and 15%
after transplantation of DBD livers, but can be as high as266 Journal of Hepatology 20130–50% after transplantation of DCD grafts [17,18]. The occur-
rence of NAS in a donor liver critically impacts patients’
long-term survival, rate of re-transplantation, quality of life and
costs of care [19,20]. Synonyms for NAS that are frequently used5 vol. 63 j 265–275
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Fig. 2. Proposed pathogenesis of NAS after liver transplantation. During warm
(in DCD donors) and cold ischemia (in both DCD and DBD livers) bile duct injury
occurs almost universally, characterized by injury and loss of the luminal biliary
epithelium. This type of injury alone does not necessarily lead to NAS. Critical
components of the bile duct wall are the peribiliary glands (PBG) and the PVP.
Severe injury to the PBGs and PVP has been associated with the development of
NAS [27] suggesting that adequate preservation of these structures is essential for
a timely regeneration of the biliary epithelium. After transplantation, biliary bile
salts may cause additional damage to the remnant luminal epithelium and diffuse
into the bile duct wall, causing injury to the PBG and PVP. Secondary inﬂux of
immune cells leads to inﬂammation with subsequent ﬁbrosis and scarring of the
bile ducts resulting in NAS. Machine perfusion of donor livers may reduce the
incidence of NAS after transplantation by reducing the amount of injury to the
various components of the bile duct wall.
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in the literature are ischemic–type biliary lesions and ischemic
cholangiopathy. In general, all three names refer to the same clin-
ical entity characterized by a combination of narrowing and
dilatations (or even intraparenchymal leakage) of the larger
intra- and extrahepatic donor bile ducts, either with or without
intraluminal sludge and cast formation, and in the presence of
a patent hepatic artery (Fig. 1A and B). Severity and distribution
of NAS along the biliary tree may vary considerably among
patients and clinical symptoms range from no symptoms to
recurrent jaundice and/or life-threatening cholangitis with sub-
sequent need for re-transplantation [21].
NAS is a feared and severe complication in DCD liver trans-
plantation, resulting in a considerable number of donor livers
that are currently being rejected for transplantation, while these
livers could potentially be used if a protective method against the
development of NAS existed. Machine perfusion is a promising
technique that has gained renewed interest in the past decade
as a tool to optimize and assess livers for transplantation.
Protection of the biliary tree as a speciﬁc target of machine per-
fusion has, however, been underexposed in the literature. In this
review we provide an update on the most recent advances in the
understanding of the etiology of NAS and present current evi-
dence supporting the hypothesis that machine perfusion reduces
bile duct injury during transplantation, providing a tool to reduce
the incidence of NAS. Moreover, we provide an overview of end-
points used for evaluation of the biliary tree in the setting of
machine perfusion.
· Non-anastomotic biliary strictures (NAS) are a major 
barrier for the widespread use of extended-criteria 
donor livers.
· Considerable progress has been made in the under-
standing of NAS.
· Surrogate endpoints have been identified to study the 
protective effect of machine perfusion on the biliary tree.
· Machine perfusion comprises a spectrum of techniques; 
different forms of machine perfusion offer protective ef-
fects on the biliary tree and may prevent NAS.
· Machine perfusion holds great promise to expand the 
donor pool by improving the quality of extended criteria 
donor livers and reducing the incidence of NAS.
Key pointsRisk factors and pathogenesis of NAS
Traditionally, the degree of biliary injury that occurs during and
after transplantation was considered to be the main determining
factor for NAS [22]. Warm and cold ischemia, reperfusion injury,
bile salt toxicity, and immune-mediated injury have been identi-
ﬁed as the most important contributors to this multifactorial pro-
cess of biliary injury [18,23]. However, three independent
histological studies focusing on the common bile duct of donor
livers revealed that in 86%-88% of cases the bile duct epitheliumJournal of Hepatology 201is already signiﬁcantly injured at the end of cold storage [24–26].
This observation indicates that the bile ducts of almost every
donor liver suffer substantial injury during graft preservation,
yet only a minority of them develop NAS after transplantation,
suggesting that the lack of regenerative capacity of the donor bile
duct may be more important than the initial degree of injury [26].
This new concept of the pathogenesis of NAS has incited inter-
est into the mechanisms involved in biliary regeneration. In a
study of 128 liver transplants, op den Dries et al. [27] have
demonstrated a strong association between injury of the peribil-
iary glands (PBG) and the peribiliary vascular plexus (PVP) at the
time of transplantation and the later development of NAS in liver
transplant recipients. The PBG are glandular structures that are
abundantly present in the wall of the extrahepatic and major
intrahepatic bile ducts, which are the most common locations
of stricture formation [21,28]. Moreover, the PBG have been
shown to be a niche for progenitor cells that can proliferate upon
biliary injury [28–32]. The fact that; i) extensive epithelial regen-
eration is necessary after transplantation in the majority of liver
grafts; ii) proliferation is observed in the PBG upon biliary injury;
and iii) loss of PBG integrity at the time of transplant is associated
to the development of NAS post-transplant strongly suggests that
the PBG are a key component required for successful recovery
from the extensive and multifactorial biliary injury that occurs5 vol. 63 j 265–275 267
Table 1. Overview of endpoints suitable for studying biliary preservation by machine perfusion.
Endpoint Variable Level of evidence* References
Non-anastomotic biliary 
strictures (NAS):
ERCP or MRCP (gold standards) IIa  [21,115]
PTCD IIa  [116]
Plastination casting (animal model) III  [117]
Established risk factors for 
NAS:
H&E staining/systematic light microscopic evaluation of 
common bile duct biopsies at time of transplantation
PVP injury III  [24,27]
Deep PBG injury III  [27]
Mural stroma necrosis III  [24,25,27]
Cholangiocyte loss III  [25]
Bile salt/phospholipid ratio in bile III  [33,42]
Cholesterol in bile III  [33]
Cholangiocyte specific microRNAs
In bile III  [42,52]
In preservation fluid III  [118]
Indicators of biliary injury with 
unknown correlation to NAS:
Immunohistochemistry of bile duct biopsies
Markers of apoptosis V  [109]
Ki-67 protein V  [32,38]
von Willebrand Factor V  [38]
Loss of cytokeratin 19 (CK19) positive cells V  [41]
Cholangiocyte function markers in bile
Bicarbonate V  [38,50,74]
pH V  [74]
Glucose V  [119]
Cholangiocyte injury markers in bile
Gamma-glutamyltransferase III  [38,50,77,98,120]
Lactate dehydrogenase III  [38,50,98,120]
* Level of evidence assessed according to oxford 2011 levels of evidence [121].
ERCP, Endoscopic Retrograde Cholangiopancreatography; MRCP, Magnetic Resonance Cholangiopancreatography, PTCD, percutaneous cholangiography drainage; H&E,
hematoxillin and eosin, PVP, peribiliary vascular plexus, PBG,s peribiliary gland.
Reviewduring transplantation. Possibly, the absence of a healthy epithe-
lial barrier due to the failure of cholangiocyte regeneration
increases prolonged bile salt cytotoxicity and inﬂammation
eventually leading to NAS [18,23,27,33].
The PVP is essential for the viability of the bile duct as it pro-
vides blood with nutrients and oxygen to the bile ducts. Blood
ﬂow through the PVP is mainly supplied by the hepatic artery
and thrombosis of the hepatic artery early after transplantation
generally leads to necrosis of the larger donor bile ducts
[34–36]. Even in the presence of a patent artery, dysfunction
and preservation injury of the PVP is believed to play a role in
the etiology of NAS [24,37]. These recent ﬁndings suggest a crit-
ical role of the PVP and the PBG in biliary regeneration and the
pathogenesis of NAS. Histology of bile ducts with various
degrees of injury of the luminal biliary epithelium, the PBG,
and the PVP are presented in Fig. 1C–F. The regenerative capac-
ity of the bile duct may be negatively inﬂuenced by known risk
factors for NAS, such as donor age and donor warm ischemia (as
occurs in DCD donors), as well as toxic bile salts that may not
only affect the luminal epithelium, but also the PBG and PVP.
Especially when the luminal biliary epithelium is absent, bile268 Journal of Hepatology 201salts can easily enter the bile duct wall stroma and cause injury
to these essential structures. Achieving protection or improved
recovery of these critical components of the bile duct wall by
machine perfusion could therefore contribute to the prevention
of NAS. Here, preventing injury altogether would be the ulti-
mate target, because when regeneration is not needed it also
cannot fail. If this cannot be accomplished, protection of the
PVP and PBG to facilitate successful regeneration through tissue
oxygenation and preservation of progenitor cells in the PBG are
obvious subsidiary goals. Not surprisingly, optimal preservation
of the PVP and PBG has become an important endpoint in
machine perfusion studies [38–40]. The proposed pathogenesis
of NAS and the various targets for machine perfusion are
summarized in Fig. 2.Assessment of the impact of machine perfusion on the biliary
tree
Accurately assessing the effect of machine perfusion on the bil-
iary tree poses a signiﬁcant challenge. Biliary function and injury5 vol. 63 j 265–275
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are frequently used as surrogate endpoints for the occurrence of
NAS. However, in general the overall degree of biliary injury does
not correlate very well with the development of NAS [26].
Unfortunately, NAS do not easily occur after liver transplantation
in rats and therefore this deﬁnitive endpoint is only obtainable in
transplantation studies of large animals or humans, which are
more complex and expensive. Nevertheless, a worthy set of end-
points, based on the current understanding of the etiology of NAS,
is available for evaluating the biliary tree in the setting of
machine perfusion (Table 1).
As discussed previously, multiple studies have indicated an
important role of the PVP and PBG in the etiology of NAS
[24,27,37]. Therefore, the effects of machine perfusion on these
structures are of particular relevance. They can be investigated
using standard light microscopy and a standardized
semi-quantitative scoring system [24,25,27]. This approach is sig-
niﬁcantly more objective compared to free-format pathological
interpretation and has emerged as an important endpoint
[38,39]. More sophisticated methods such as immunohistochem-
istry may also be used. For example, Ki67 and CK19 are markers
for proliferation in the PBG and the bile duct epithelium respec-
tively [32,38,41]. The expression of von Willebrand Factor on the
vascular endothelium indicates endothelial cell activation that
can lead to platelet aggregation in the PVP [38].
Bile salt toxicity is known to be another important pillar in the
mechanism of NAS [18]. The epithelial lining forms a specialized
barrier to protect the bile duct from the detergent effects of bile.
Hepatocytes excrete phospholipids that form mixed micelles,
neutralizing the detergent effect of bile salts. When this barrier
is impaired by ischemia/reperfusion induced injury or dysfunc-
tion, toxic bile salts can cause additional harm to the biliary
epithelium, or when this is already absent, to the unprotected
sub-mucosal stroma and the deeper located structures such as
PBG and PVP [33,42]. Consequently, the ratio of bile salts to phos-
pholipids in bile during perfusion is an important marker of the
endogenous protective mechanisms against bile salt toxicity.
The same is true for the biliary concentration of bicarbonate
(HCO3), which prevents the protonation of biliary
glycine-conjugated bile salts and uncontrolled cell entry of the
corresponding bile acids through cell membranes by raising the
pH, a phenomenon known as the ‘‘bicarbonate umbrella’’ [43].
Bicarbonate is actively secreted into the bile by the biliary epithe-
lial cells (or cholangiocytes) and, therefore, biliary bicarbonate
concentration can also be used as a biochemical marker of
cholangiocyte function [18]. Moreover, disruption or imbalanceSubnormo
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Fig. 3. Schematic presentation of the various dimensions of machine perfusion. DCD
Journal of Hepatology 201of bile salt transportation, which is an ATP dependent process,
can contribute to injury by the intracellular accumulation of
hydrophobic bile salts [44,45].
The production of bile involves a cascade of steps that requires
good function of all its components, including both hepatocytes
and cholangiocytes [46]. Therefore, the rate of bile production
during machine perfusion, in combination with the characteris-
tics of its composition, is an excellent indicator of both liver
and biliary function [47]. Glucose is initially present in the
canalicular bile at a concentration equal to plasma and is subse-
quently reabsorbed by the cholangiocytes of the bile ducts. A low
glucose concentration (<1.0 mmol/L) in the common bile duct
bile, therefore, indicates adequately functioning biliary epithelial
cells, and can be used as a target for assessing bile duct integrity
during machine perfusion [48,49].
Markers of cellular injury, such as lactate dehydrogenase and
gamma-glutamyltransferase, can be measured in bile and per-
fusate [38,50]. Although they may reﬂect the degree of biliary
injury, it is unknown whether high biliary levels of these injury
markers are associated with the later development of NAS. One
method that holds promise is the detection of cholangiocyte
speciﬁc micro RNAs in bile that have been associated with the
development of NAS [51,52].
Obviously, the incidence of NAS during follow up after trans-
plantation of machine-perfused grafts is the most relevant end-
point in determining the effect of machine perfusion on biliary
complications. Randomized clinical trials are needed to elucidate
the effect of machine perfusion on biliary complications in
humans.Machine perfusion: a spectrum of techniques
The term ‘machine perfusion’ is very broad; it covers a spectrum
of techniques with mechanical perfusion as their common
denominator. Fundamentally, the conﬁguration of machine per-
fusion depends on three parameters: the timing and duration of
its application, and the perfusion temperature. In order to pre-
vent endothelial shear stress, pressure controlled perfusion is
considered to be a safer method compared to ﬂow controlled
perfusion [53].
Perfusion through the portal vein is only feasible at low tem-
peratures [54,55]. But from the perspective of biliary preserva-
tion, arterial perfusion and the delivery of oxygen to the bile
ducts seems paramount because the biliary system dependsNormothermic (37 °C)
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mainly on the arterial circulation [40,56]. Additionally, oxy-
genated perfusion of the arterial system has been described to
attenuate arteriolonecrosis of the PVP and therefore may con-
tribute to preservation of the vasculature to the bile ducts [39].
On the other hand, it should be noted that in contrast to tradi-
tional belief, blood is also supplied to the bile ducts by the portal
vein [57] and insufﬁcient portal perfusion should also be consid-
ered a risk factor for the development of NAS [58,59]. An argu-
ment against cannulation and perfusion of the hepatic artery is
the potential risk of causing intima injury or vascular dissection.
This risk can be minimized by using a cylindrical aortic segment
for cannulation, which can be cut off and discarded at the end of
perfusion before implantation.
Machine perfusion can be applied at different time points dur-
ing the process of procurement, transportation, and transplanta-
tion, as summarized in Fig. 3. The earliest possible application of
machine perfusion in the chain of events is in situ normothermic
regional perfusion (NRP) in the donor, immediately after circula-
tory arrest. It offers the advantage of restoring cellular levels of
ATP that have become depleted during the period of warm ische-
mia by restoration of normothermic circulation in the donor prior
to standard cold storage [60]. The technique has been success-
fully used in clinical DCD organ donation, and its effect on preser-
vation of the bile ducts and the rate of biliary complications
seems promising [61–63]. Investigators from the Hospital Clinic
in Barcelona have reported 42 liver transplant procedures after
NRP of DCD donors with a biliary complication rate of 17% [63].
Another group, from the University of Michigan, has described
13 liver transplant procedures using this method with an inci-
dence of biliary complications of 14% [62]. While these outcomes
are very hopeful, both studies lacked a control group and were
not randomized. Also, in one report 38% of donor livers were dis-
carded because of technical complications, illustrating the com-
plexity of NRP [62]. Randomized controlled trials are necessary
to assess the clinical beneﬁts of NRP.
Ex situ machine perfusion of the liver can be performed at the
donor site before cold storage (pre-storage perfusion), at the
receiving hospital after cold storage prior to implantation
(end-ischemic perfusion), or throughout the preservation period
(preservation perfusion) (Fig. 3) [64,65]. The advantage of
pre-storage perfusion is that it has the ability to restore the
energy charge of the liver prior to subjecting it to cold ischemia,
potentially reducing the synergistic accumulation of injury
caused by subsequent warm and cold ischemia. However, accom-
plishing on-site machine perfusion in donor hospitals is troubled
by several logistical challenges.
These challenges are even more pronounced in preservation
perfusion, which requires a machine perfusion device that is
portable and self-sufﬁcient for the duration of the preservation
period. Theoretically, continuous preservation perfusion is the
most optimal choice because it eliminates the need for cold
storage. Normothermic preservation perfusion has been success-
fully used in a clinical trial including liver transplantation of ten
patients [66]. Although continuous normothermic preservation
perfusion may prove to be the most effective preservation
method in the future, it is questionable whether complete elim-
ination of cold preservation is necessary and cost-effective in
the current era.
End-ischemic perfusion offers the advantage that it can be
performed in the environment of the transplant center with all
the logistic support needed for successful perfusion. Although270 Journal of Hepatology 201logistically appealing, irreversible injury may have occurred
already to the liver and the biliary tree, which might have been
preventable or treatable upon earlier intervention. Finally,
through both preservation perfusion and end-ischemic perfusion,
the organ can be optimized immediately prior to implantation,
which is not the case for pre-storage perfusion. In general,
machine perfusion requires speciﬁc surgical training and the
direct costs are higher compared to simple cold storage.
However, the technique could be cost-effective and even lead
to lower overall costs due to shorter postoperative length of stay
and reduction of the incidence of NAS, but studies of
cost-effectiveness are needed to clarify this. Promisingly, renal
machine perfusion has been proven to be cost-effective [67,68].Temperature
The cellular rate of respiration is greatly dependent on the tem-
perature, following an exponential curve [69]. Simple static cold
storage at 0–4 C is based on this principle and reduces the meta-
bolic rate of the liver to about 5% of the physiological level.
Because of this relationship, the temperature used during
machine perfusion dictates the calibration of most other perfu-
sion parameters that should be optimized to meet the dynamics
and metabolic needs of the organ at a given temperature.Hypothermic machine perfusion
Under hypothermic conditions (0–10 C), the use of an acellular
perfusion ﬂuid at low pressures is most common. The use of red
blood cells or an oxygen carrier is not necessary, because adequate
uptake of oxygen into the ﬂuid can be achieved through diffusion
at low temperatures [70]. Hypothermic machine perfusion (HMP)
is safe because in case of pump failure, the organ falls back on the
‘default’ conditions of static cold preservation. The low metabolic
activity that is associated with hypothermic perfusion conditions
also forms a limitation, because it does not allow a functional
assessment of the liver. For example, the liver does not produce
bile during HMP, which is an important indicator of hepatobiliary
function and allows biochemical assessment of biliary markers of
biliary epithelial cell function and injury [50,71].
A large number of studies using HMP in animal models have
been performed; however, few studies have evaluated the effects
of HMP on the biliary system [53]. Using a non-arterialized model
of DCD liver transplantation in rats, Schlegel et al. [41] compared
one hour of end-ischemic hypothermic oxygenated machine per-
fusion to cold storage alone. After four weeks of follow up, ani-
mals from the HMP group presented with superior histological
appearance of the intrahepatic bile ducts and signiﬁcantly lower
serum gamma-glutamyltransferase, alkaline phosphatase and
bilirubin [41]. In another experimental study, our group has com-
pared 4 h of hypothermic oxygenated perfusion to cold storage of
DCD pig livers, followed by 2 h of normothermic blood reperfu-
sion to simulate transplantation. Although, no differences in bil-
iary epithelial function or injury were observed, oxygenated HMP
did lead to superior preservation of the PVP, which may have a
positive impact on blood supply to the bile ducts and their regen-
erative capacity after transplantation [39].
Guarerra and coworkers, who were the ﬁrst to describe suc-
cessful clinical transplantation of HMP preserved liver grafts in5 vol. 63 j 265–275
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2010 [54], recently reported the outcome of the ﬁrst 31 cases per-
formed in their center [72]. Apart from generally improved out-
come parameters (shorter length of stay, lower postoperative
serum injury markers etc.), the number of biliary strictures in
the HMP preserved group was signiﬁcantly lower compared to
matched controls (10% after HMP vs. 33% after SCS). It should
be noted that the perfusion system used by Guarerra and cowork-
ers does not provide active oxygenation of the perfusion ﬂuid and
the duration of perfusion was not standardized. Dutkowski et al.
[55] have applied oxygenated HMP, or hypothermic oxygenated
perfusion (HOPE), to eight locally procured DCD livers before
transplantation and compared the outcomes with matched DBD
controls. The rate of biliary complications was identical between
the two groups; however, the numbers were too low to draw any
robust conclusion on the incidence of biliary strictures. Despite
the fact that livers were perfused through the portal vein only
and the study lacks a DCD control group, it suggests a possible
protective effect of HOPE against bile duct injury. A clinical trial
with hypothermic oxygenated dual perfusion of DCD livers
(through both the portal vein and hepatic artery) was recently
initiated in our center (Netherlands Trial Registry, NTR4493;
www.trialregister.nl). Final assessment of the efﬁcacy of HMP
(either oxygenated or non-oxygenated) in reducing biliary injury
and subsequent NAS should come from large multicenter ran-
domized clinical trials. Several initiatives to organize such trials
have been taken (i.e. ClinicalTrials.gov, ID: NCT01317342).Subnormothermic machine perfusion
Subnormothermic machine perfusion (SNMP, 20–30 C) is a
middle-of-the-road approach between HMP and normothermic
machine perfusion (37 C, NMP) [73]. An advantage of SNMP is
its relative simplicity compared to NMP. By inducing a metabolic
rate of approximately 25% of physiological levels, it allows for
functional assessment of the liver [74]. To prevent depletion of
nutrients, SMP requires the use of a nutrient enriched perfusate.
Surprisingly, an oxygen carrier is not always used; SMP has been
performed both with and without red blood cells or an artiﬁcial
oxygen carrier [73,75,76]. The question whether the use of an
oxygen carrier at subnormothermic temperatures is essential,
therefore, remains a matter of debate and this issue requires fur-
ther research.
SNMP has been tested in rats with positive effects on bile pro-
duction and decreased release of biliary enzymes [77,78]. Using a
hepatocyte cell culture medium as a perfusate, Bruinsma et al.
[74] performed SNMP of seven human livers that were declined
for transplantation. During 3 h of end-ischemic SNMP, increasing
bile ﬂow and biliary bicarbonate excretion were seen. Moreover,
the ratio of bile salts to phospholipids in bile decreased over time,
indicating improvement of hepatocellular secretory function and
a decrease in bile toxicity. Unfortunately, this study had no con-
trol group or reperfusion phase; therefore it provides little sub-
stantiation for SNMP beyond proof of feasibility [74].
Knaak et al. [79] have performed liver transplantation after
SNMP of DCD pig livers, comparing it to static cold storage. The
three hour perfusion phase in this experiment, using Steen’s solu-
tion with washed red blood cells at 33 C, was preceded by four
hours, and followed by three hours of cold ischemia time. The
investigators ﬁrst studied bile output of the liver during eight
hours of in situ reperfusion. Subsequently, ten animals (ﬁve vs.ﬁve)Journal of Hepatology 201were transplanted andmonitored for seven days. Lactate dehydro-
genase in the bile was found to be signiﬁcantly lower immediately
after transplantation in the SNMP group. Moreover, cold stored
grafts presented with substantial bile duct necrosis after seven
days, but those that preserved with SNMP did not. This was also
reﬂected in the serum levels of alkaline phosphatase during the
survival period,whichwere signiﬁcantly higher in the cold storage
group. This study indicates that SNMPhas protective effects on the
bile ducts in a DCD model of pig liver transplantation.Normothermic machine perfusion
Under normothermic conditions, the liver reaches a physiological
metabolic rate and functionality. Sufﬁcient oxygen delivery can
only be achieved with the use of an oxygen carrier. This form
of machine perfusion has been studied extensively in experimen-
tal models by the group of Friend and coworkers [66,71,80,81]
and enables ex situ viability testing of the liver [50]. Some argue
that it is superior to cold perfusion because it provides the closest
resemblance to the normal physiological situation in vivo [82].
However, bringing the organ up to ‘full metabolic speed’ also
makes it more vulnerable. Interruption of perfusion or insufﬁ-
cient oxygen delivery will immediately expose the liver to warm
ischemia. Remaining mindful of this risk, NMP can be safe and
reliable when performed correctly [83–86].
NMP appears to be the category of perfusion that provides the
most pronounced effects on biliary preservation. In an interesting
experiment using pig DCD livers, Liu et al. [38] assessed the effect
of 10 h of NMP on biliary injury and regeneration during 24 h of
ex vivo reperfusion. The study showed lower release of injury
markers (gamma-glutamyltransferase and lactate dehydroge-
nase) in bile and increased biliary bicarbonate secretion in NMP
preserved livers, compared to livers that underwent conventional
10 h of static cold storage. Moreover, NMP preserved livers dis-
played signiﬁcantly less histological injury of the PBG and PVP,
produced more bile, and demonstrated lower thrombogenicity
of the microvasculature. Additionally, using Ki-67 staining, these
investigators observed proliferation of cholangiocytes during
24 h of reperfusion of NMP preserved grafts, which was not seen
in livers preserved by static cold storage. This study provides
important evidence that 10 h of NMP yields superior results with
regard to biliary injury and regeneration, compared to static cold
storage [38]. It should however, be noted that this study did not
include actual transplantation of machine-perfused livers and,
therefore, the occurrence of NAS after transplantation was not
assessed.
Boehnert et al. [87] have published an experimental study
showing extraordinary biliary preservation by NMP in a DCD pig
model. Although their experiment offers new perspectives on
NMP, such as through the use of CT angiography, this study have
been criticized for its design and difﬁculty to explain the outcomes
[88,89]. Our groupwas the ﬁrst to publish on the feasibility of NMP
in four discarded human livers using six hours of perfusion in an
end-ischemic approach [50]. During the six hours ofNMP, bile duct
histology remained well preserved and did not deteriorate. After
expanding this series to a total of 12 livers, we found that bile pro-
duction during NMP can be used as a predictor of graft function,
enabling viability testing [47]. This ﬁnding is in line with previous
animal studies of NMP,which have recognized bile production as a
critical parameter of viability of the perfused liver [71,83,90].5 vol. 63 j 265–275 271
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Several (randomized) clinical trials have been initiated recently
andhopefully these studieswill provide evidence for the beneﬁcial
effects of machine perfusion on the incidence of biliary complica-
tions after liver transplantation. In one randomized controlled
multicenter trial normothermic preservation perfusion will be
compared with static cold storage (http://www.controlled-tri-
als.com/ISRCTN39731134/). Another multicenter trial is investi-
gating the possible protective effects of NRP in DCD donors
(http://www.controlled-trials.com/ISRCTN89667087/).Controlled rewarming
The abrupt change in temperature that occurs upon reperfusion
during transplantation of a hypothermic liver is believed to con-
tribute to reperfusion injury. Many research groups have
explored machine perfusion strategies at a constant temperature,
still exposing the liver to sudden temperature changes. Minor
et al. studied the effect of controlled oxygenated rewarming
(COR) of the liver from ice-cold to subnormothermic tempera-
tures during perfusion and compared this method with HMP
and SNP alone [91]. In this experiment, pig livers were harvested
and preserved by cold storage for 18 h, followed by 90 min of
SNP, HMP or COR. The organs where subsequently re-perfused
ex vivo normothermically with autologous blood to simulate
transplantation. Energy charge restoration during COR was simi-
lar to SMP, but superior to HMP. In addition, COR was associated
with signiﬁcantly better hepatobiliary function (as indicated by
bile production) and less injury upon reperfusion. A group from
Tokyo has described similar results [92,93]. Integrating con-
trolled rewarming into perfusion protocols could potentially
combine the best of cold and warm perfusion techniques and
may potentially provide better protection of the bile ducts.Perfusate composition
The composition of the perfusion ﬂuid is guided primarily by the
temperature, timing and duration of machine perfusion. Whereas
at low temperatures a low-nutrient preservation solution may be
used, increasing duration and temperature of perfusion necessi-
tates more additives. Irrespective of these factors, oxygen deliv-
ery through the perfusate is a fundamental pillar of the
advantages that machine perfusion has to offer to both the liver
and the bile ducts [56,94–96]. When oxygen consumption
exceeds the delivery potential of dissolved oxygen in a watery
ﬂuid, red blood cells or an artiﬁcial oxygen carrier should be
added [38,50,97]. Because the hepatobiliary transporters that
are responsible for bile formation are calcium dependent, it is
important to titrate calcium to physiological levels for the opti-
mization of biliary secretory function [46,98]. This is especially
true when blood products are added to the perfusate, which usu-
ally contain calcium-scavenging agents such as citrate. Bile salts
excreted by the liver during machine perfusion do no return to
the perfusate, which normally happens through the enterohep-
atic circulation in vivo. Supplementation of bile salts is therefore
necessary when applying machine perfusion for extended periods
of time to ensure sustained bile production [71]. Another relevant
aspect is the viscosity of the solution. Several studies have indi-
cated that low-viscosity solutions may achieve superior perfusion
of the peribiliary vasculature [99–102]. However, the effect of272 Journal of Hepatology 201low-viscosity cold ﬂush solutions on biliary complications is con-
troversial [103]. Other constituents of machine perfusion solu-
tions may be oncotic agents (e.g. albumin), parenteral nutrition,
antibiotics, insulin, heparin, and vasoactive drugs [38,50,104].
Machine perfusion also opens alleyways towards ex situ treat-
ment of the liver to enhance the preservation even further. As
these techniques are still speculative, they will be discussed as
‘future directions’.
Many combinations of perfusion temperatures, perfusates,
time points and durations have been explored. For a more
detailed overview of particular conﬁgurations, we suggest further
reading of speciﬁc reviews [53,105–108]. Which combination of
these parameters provides optimal protection for the biliary tree
currently remains unclear.Future directions
Machine perfusion provides a platform that may facilitate the
treatment of donor livers, uncovering speciﬁc targets that previ-
ously remained out of reach for the transplant surgeon. One pos-
sibility that quickly comes to mind is the addition of
pharmacological agents to the perfusion ﬂuid. Such interventions
could be speciﬁcally targeted at factors that have been shown to
play a role in the pathogenesis of NAS, such as bile composition,
immunological factors, bicarbonate secretion, or even factors that
may stimulate biliary epithelial regeneration.
With the aim of reducing the Kupffer cell-mediated insult to
the liver after transplantation, one group has administered
gadolinium chloride (GdCl3) to rats in an autologous rat trans-
plant model. This intervention reduced the amount of apoptosis
observed in the bile duct after warm ischemia/reperfusion injury
[109]. Another prospect could be the addition of hydrophilic bile
salts or other compounds to stimulate a less cytotoxic bile com-
position [71].
Finally, it has been proposed that the infusion of MSCs into the
perfusion circuit could help restore a donor organ [110]. Although
the exact mechanisms are unknown, MSCs are believed to have
anti-inﬂammatory and pro-regenerative effects mostly through
the excretion of paracrine factors without requiring colonization
[111,112]. The clinical safety of MSC infusion in liver transplant
recipients has been suggested, but the efﬁcacy is still strongly
debated [113,114]. Machine perfusion provides an exceptional
opportunity for the ex situ application of MSCs.Conclusion
Liver machine perfusion comprises a spectrum of promising
techniques of liver graft preservation that are currently making
the transition into clinical practice. It is anticipated that the
use of machine perfusion can lead to a signiﬁcant increase of
the availability of transplant livers as well as a reduction in post-
operative complications such as early graft dysfunction and bil-
iary complications. Existing data from animal models and
preliminary data from (discarded) human donor livers provide
promising evidence that machine perfusion has relevant protec-
tive effects on the bile ducts. In animal studies, liver machine
perfusion did not only reduce the amount of injury to the bile
ducts, but it also helped to restore the endogenous regenerative
capacity of the biliary epithelium and bile duct wall. Whether5 vol. 63 j 265–275
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this results in a decreased incidence of biliary complications,
such as NAS, after clinical transplantation needs to be awaited.
Randomized clinical trials are being initiated and will be neces-
sary to demonstrate the efﬁcacy of machine perfusion in clinical
transplantation. Finally, machine perfusion provides a platform
for the exploration of putative ex situ treatments, using interven-
tions that are aimed at speciﬁc targets in the liver and the biliary
system.Conﬂict of interest
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